Tango Therapeutics
TNGX
82 hedge funds and large institutions have $498M invested in Tango Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 17 closing their positions.
102% more capital invested
Capital invested by funds: $247M → $498M (+$252M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 21
0.55% more ownership
Funds ownership: 77.41% → 77.96% (+0.55%)
6% less funds holding
Funds holding: 87 → 82 (-5)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.4M |
| 2 |
BlackRock
New York
|
+$4.44M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$1.77M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.41M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$4.24M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.95M |
| 3 |
Goldman Sachs
New York
|
-$1.44M |
| 4 |
Millennium Management
New York
|
-$1.24M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$949K |
TNGX Hedge Fund Activity: Q4 2022 in Review
82 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q4 2022, worth a combined $498M — up 102% from $247M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TNGX and 12 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 30 added.
The largest buyer was Fidelity Investments, adding an estimated $14.4M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $4.24M sold.
- 82 institutional investors held Tango Therapeutics (TNGX) as of Q4 2022, down from 87 in Q3 2022.
- Funds reported $498M of Tango Therapeutics stock for Q4 2022, up 102% quarter-over-quarter.
- 12 funds opened new Tango Therapeutics positions in Q4 2022 and 17 closed out, a net change of -5 holders.
- The largest Tango Therapeutics buyer in Q4 2022 was Fidelity Investments, an estimated $14.4M added.
- The largest Tango Therapeutics seller in Q4 2022 was TCG Crossover Management, an estimated $4.24M sold.
Based on aggregated 13F filings for Q4 2022.